Biomarkers in melanoma
Helen Gogas(National and Kapodistrian University of Athens), R. Dummer(University of Zurich), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Alan Spatz(Jewish General Hospital), Alexander M.M. Eggermont(University Medical Center Utrecht), Peter Hersey(The University of Sydney), Axel Hauschild(University Hospital Schleswig-Holstein), Dirk Schadendorf(National Center for Tumor Diseases)
Cited by 141
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k